Pharmacokinetic-Pharmacodynamic Relationship of the Selective Serotonin Reuptake Inhibitors

@article{Baumann1996PharmacokineticPharmacodynamicRO,
  title={Pharmacokinetic-Pharmacodynamic Relationship of the Selective Serotonin Reuptake Inhibitors},
  author={Pierre Baumann},
  journal={Clinical Pharmacokinetics},
  year={1996},
  volume={31},
  pages={444-469}
}
  • P. Baumann
  • Published 1996
  • Medicine
  • Clinical Pharmacokinetics
SummaryThe recently introduced antidepressants, the selective serotonin reuptake inhibitors (SSRIs) [citalopram, fluoxetine, fluvoxamine, paroxetine and sertraline], are known for their clinical efficacy, good tolerability and relative safety. They differ from each other in chemical structure, metabolism and pharmacokinetic properties. Therapeutic drug monitoring of these compounds is not widely used, as the plasma concentration ranges within which clinical response with minimal adverse effects… Expand
Pharmacokinetics of selective serotonin reuptake inhibitors.
TLDR
Different pharmacokinetic properties of the five SSRIs, especially their drug-drug interaction potential, should be considered when selecting a distinct SSRI for treatment of depression or other disorders with a suggested dysfunction of the serotonergic system in the brain. Expand
Metabolism and Pharmacokinetics of Selective Serotonin Reuptake Inhibitors
  • C. DeVane
  • Medicine
  • Cellular and Molecular Neurobiology
  • 2004
TLDR
The metabolism and relevant pharmacokinetic properties of the SSRIs are summarized, appearing to share similar pharmacodynamic properties which translate to efficacy in the treatment of depression and anxiety syndromes. Expand
Metabolic drug interactions with new psychotropic agents
TLDR
The potential for metabolically based drug interactions of any new psychotropic agent may be anticipated on the basis of knowledge about the CYP enzymes responsible for its metabolism and about its effect on the activity of these enzymes. Expand
Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review
TLDR
Although no clear relationship exists between the clinical efficacy, plasma concentration of SSRIs, nor any threshold that defines toxic concentrations, therapeutic drug monitoring (TDM) may be useful in special populations, such as in elderly patients, poor metabolizers (PM) of sparteine or mephenytoin (CYP2C19), and patients with liver and kidney impairment. Expand
The influence of selective serotonin reuptake inhibitors on the plasma and brain pharmacokinetics of the simplest phenothiazine neuroleptic promazine in the rat
TLDR
All the three SSRIs administered chronically in pharmacological doses, increase the concentrations of promazine in the blood plasma and brain of rats by inhibiting different metabolic pathways of the neuroleptic. Expand
Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors?
TLDR
In several studies there has not been found a clear relationship between clinical efficacy and plasma concentration, nor any threshold that defines toxic concentrations, so therapeutic drug monitoring (TDM) of the SSRIs may be useful mainly in situations where poor compliance is suspected and when therapeutic failure or toxic events are experienced at clinically relevant dosages. Expand
Stereoselective HPLC-assay for citalopram and its metabolites.
TLDR
The present assay allows a rapid, sensitive, and reliable stereoselective determination of CIT and its (active) metabolites which can be applied for assessing pharmacokinetic parameters and evaluating putative relationships to clinical (side) effects. Expand
Metabolism of the Newer Antidepressants
  • S. Caccia
  • Medicine
  • Clinical pharmacokinetics
  • 1998
TLDR
Several chemically unrelated agents has been developed and introduced in the past decade, to supplement the earlier antidepressants, as well as drugs with distinct neurochemical profiles such as mirtazapine, nefazodone, moclobemide and tianeptine, which may explain the individual variability with all these drugs. Expand
Therapeutic drug monitoring of non-tricyclic antidepressant drugs
  • P. Mitchell
  • Medicine
  • Clinical chemistry and laboratory medicine
  • 2004
TLDR
Therapeutic drug monitoring (TDM) of many of the tricyclic antidepressants (TCAs) has been demonstrated to be of clear clinical value and potential future applications of TDM, in conjunction with genotyping of cytochrome P450 enzymes and pharmacogenomic evaluations, are discussed. Expand
Clinical Uses and Differences Among the Selective Serotonin Reuptake Inhibitors
TLDR
The selective serotonin reuptake inhibitors are the most commonly prescribed agents for treating depressive disorders in the United States and have a different pharmacodynamic and tolerability profile from other antidepressants. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 164 REFERENCES
Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror
TLDR
It is concluded that for routine therapeutic drug monitoring, the plasma level measurement of the enantiomers of citalopram and fluoxetine is probably of little relevance, but for the study of the structure-activity relationship between these drugs and the cerebral 5-HT transporter, the stereochemical differences of these enantiomer should be considered. Expand
Clinical Pharmacokinetics of Selective Serotonin Reuptake Inhibitors
TLDR
Although many attempts were made, to date no convincing evidence exists of a relationship between plasma concentrations of any of the SSRIs and clinical efficacy, and available data indicate that metabolism ofSSRIs is impaired with reduced liver function. Expand
Clinically Relevant Pharmacology of Selective Serotonin Reuptake Inhibitors
  • S. Preskorn
  • Biology, Medicine
  • Clinical pharmacokinetics
  • 1997
TLDR
An overview of the clinically relevant pharmacology of selective serotonin reuptake inhibitors (SSRIs) with an emphasis on their pharmacokinetics and effects on cytochrome P450 (CYP) enzymes is presented. Expand
Overview of the Pharmacokinetics of Fluvoxamine
TLDR
Fluvoxamine pharmacokinetics are substantially unaltered by increased age or renal impairment, however, its elimination is prolonged in patients with hepatic cirrhosis, and has the potential for clinically significant drug interactions. Expand
Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline
  • S. Preskorn
  • Medicine
  • International clinical psychopharmacology
  • 1994
TLDR
Sertraline is notable for having few clinically meaningful drug interactions at its usually effective, minimum dose, and at their usually effective minimum dose can inhibit the hepatic isoenzyme CYP2D6, which is important in the oxidative metabolism of a variety of drugs. Expand
Pharmacokinetic Optimisation of Therapy with Newer Antidepressants
  • P. Goodnick
  • Chemistry, Medicine
  • Clinical pharmacokinetics
  • 1994
TLDR
The antidepressants best suited for pharmacokinetic optimisation of therapy are the following: desipramine, sertraline, fluvoxamine, citalopram and amfebutamone, which stands out as having the best effects on behaviour among all antidepressants. Expand
Clinical Pharmacokinetics of Fluvoxamine
TLDR
Fluvoxamine pharmacokinetics are substantially unaltered in the elderly, whereas higher plasma drug concentrations (relative to dose) are observed in patients with alcoholic cirrhosis of the liver, and preliminary data suggest that plasmaDrug concentrations may increase non-linearly with increasing daily dosage. Expand
Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive-compulsive disorder.
TLDR
Sertraline appears to possess antidepressant efficacy similar to that of amitriptyline and dothiepin, marginally better than imipramine, and significantly better than placebo, and preliminary findings suggest that the drug may also be effective in the treatment of obsessive-compulsive disorder. Expand
Pharmacogenetics and Drug Metabolism of Newer Antidepressant Agents
TLDR
In patient management, it is important to consider the fact that most antidepressants can also act as enzyme inhibitors, which have the potential of causing drug interactions and can be minimized or avoided by following simple clinical logic. Expand
Clinical Pharmacokinetics of Fluoxetine
TLDR
There appears to be a therapeutic window for fluoxetine, and the pharmacokinetics of this drug are not affected by either obesity or renal impairment, which makes this drug particularly suitable for use in elderly patients with depression. Expand
...
1
2
3
4
5
...